Categories: News

Cambridge Isotope Laboratories, Inc. is Now Offering Cannabis Standards for MS-based Testing

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

TEWKSBURY, Mass., Aug. 31, 2021 /PRNewswire/ — CIL now offers solutions for testing the quality and safety of Cannabis products with the launch of a variety of stable-isotope labeled and native standards of THC, CBD, and other cannabinoids to assist with testing needs.

Research suggests the cannabis plant produces between 80-100 cannabinoids, primarily cannabidiol (CBD) and tetrahydrocannabinol (THC). The complexity and diversity of cannabis products poses unique challenges to accurate quality testing and Cannabis testing laboratories must meet the needs of varying state and federal requirements to ensure products are safe, effective, and consistent.

Ben Priest, Business Development Manager for Environmental Products at CIL, states “The increased use of mass spectrometry in cannabis testing has enabled testing facilities to offer a greater degree of accuracy and precision. CIL’s high purity analytical reference standards facilitate accurate strain identification, potency testing, and adulterant analysis.” 

“The cannabis reference standards provide an accurate analytical means to measure and quantify the presence and concentration of targets in a wide range of samples, including plant material, pharmaceuticals, personal care products, food, and beverages, says CIL’s Senior Applications Chemist, Mass Spectrometry, Andrew Percy, Ph.D. “Due to their high characterization, users can be assured that the CIL standards implemented for method development and application will lead to robust and accurate results that can be trusted in safety, quality, stability, and consistency testing.”

To learn more about CIL’s Cannabis testing standards including cannabinoids and other common pesticides related to cannabis testing, visit isotope.com.

About Cambridge Isotope Laboratories, Inc.   

CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France.   

For more information on CIL, visit isotope.com.

Contact Information:
Crissy Krisko
Phone: 1.978.749.8000 
Fax: 1.978.749.2768 
www.isotope.com

Related Images

cambridge-isotope-laboratories-inc.jpg
Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cambridge-isotope-laboratories-inc-is-now-offering-cannabis-standards-for-ms-based-testing-301365755.html

SOURCE Cambridge Isotope Laboratories, Inc.

Staff

Recent Posts

TE Connectivity declares quarterly dividend

GALWAY, Ireland, June 11, 2025 /PRNewswire/ -- TE Connectivity plc (NYSE: TEL) announced today that…

4 hours ago

SRM Equity Partners Acquires RF Technologies, a Leader in Safety and Security Solutions for Healthcare and Senior Living

BROOKFIELD, Wis., June 11, 2025 /PRNewswire/ -- SRM Equity Partners ("SRM"), an operationally focused private…

4 hours ago

New Findings from NSC Grant Recipients Help Tackle America’s Most Common Workplace Injury

MSD Solutions Lab programs unite academic researchers and industry partners to drive innovation WASHINGTON, June…

4 hours ago

Version 3.0 AI Automation Platform Launches at VGM’s Heartland Conference

Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without…

4 hours ago

AllSci Wins Grant to Expand AI Platform for Pharma and Biotech R&D: Accelerating Hypothesis-Driven Discovery

Empowering researchers at every level to test hypotheses, validate findings, and collaborate to advance science…

4 hours ago

RIVANNA selected for prestigious MedTech Innovator 2025 Accelerator Cohort

— One of 65 startups chosen from nearly 1,500 global applicants — — Selected to…

4 hours ago